Skip to content

Drug interactions

Elagolix + Rimegepant

Severity: Moderate

Elagolix and Rimegepant: moderate interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Elagolix has mixed effects, weakly inducing CYP3A4 while inhibiting P-glycoprotein, so rimegepant exposure may change unpredictably. Both reduced efficacy and increased adverse effects are possible.

What this interaction means in plain words

Elagolix and Rimegepant can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.

Elagolix belongs to Musculoskeletal; Rimegepant belongs to Central Nervous System.

Evidence level: Low

Why it happens

Elagolix induces CYP3A4 and inhibits P-glycoprotein, with opposing effects on rimegepant exposure.

What to do

Avoid the combination if possible. If used, monitor for tolerability and efficacy and avoid repeat rimegepant doses within 48 hours.

What to ask your pharmacist

  • Should I take them at different times of day?
  • Does the dose of either medicine need to change?
  • Is there anything I should avoid, such as alcohol or certain foods, while on both?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Elagolix and Rimegepant, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Elagolix with Rimegepant?

MediHelp rates the interaction as moderate. Elagolix and Rimegepant can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Elagolix has mixed effects, weakly inducing CYP3A4 while inhibiting P-glycoprotein, so rimegepant exposure may change unpredictably. Both reduced efficacy and increased adverse effects are possible.

How serious is the interaction between Elagolix and Rimegepant?

MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid the combination if possible. If used, monitor for tolerability and efficacy and avoid repeat rimegepant doses within 48 hours.

What other medicines interact with Rimegepant?

MediHelp also lists interactions of Rimegepant with, for example, Amobarbital, Atazanavir, Butabarbital. The full list is on the Rimegepant page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in